Brief: Leads Biolabs Announces Partner Oblenio Bio’S $62 Million Oversubscribed Series B Financing To Advance Tri-Specific T-Cell Engager Lbl‑051 For Autoimmune Diseases Into Clinical Development
25/06/2026 12:21
BRIEF-Leads Biolabs Announces Partner Oblenio Bio’S $62 Million Oversubscribed Series B Financing To Advance Tri-Specific T-Cell Engager Lbl‑051 For Autoimmune Diseases Into Clinical Development June 25 (Reuters) - Nanjing Leads Biolabs Co Ltd 9887.HK:
LEADS BIOLABS ANNOUNCES PARTNER OBLENIO BIO’S $62 MILLION OVERSUBSCRIBED SERIES B FINANCING TO ADVANCE TRI-SPECIFIC T-CELL ENGAGER LBL‑051 FOR AUTOIMMUNE DISEASES INTO CLINICAL DEVELOPMENT
NANJING LEADS BIOLABS CO - SERIES B ROUND LED BY PFIZER VENTURES WITH DEEP TRACK CAPITAL, GV, AND ADITUM BIO
Source text: ID:nGNX9R9c4R
Further company coverage: 9887.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials